SUN vs BEV + IFN in first-line mRCC therapy: No evidence for a statistically significant difference in progression-free survival

2010

British Journal of Cancer , Volume 102 - Issue 1 p. 232- 233

Additional Metadata
Persistent URL	doi.org/10.1038/sj.bjc.6605446, hdl.handle.net/1765/52178
Journal	British Journal of Cancer
Organisation	Erasmus School of Health Policy & Management (ESHPM)
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Nuijten, M., & Mickisch, G. H. J. (2010). SUN vs BEV + IFN in first-line mRCC therapy: No evidence for a statistically significant difference in progression-free survival. British Journal of Cancer, 102(1), 232–233. doi:10.1038/sj.bjc.6605446

Publication